All In Biotech

Free tool

FAERS Monitor: Evamist

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022014 or its brand name (Evamist, Estradiol). Reports on generic versions are filed under their own applications.

Reports

47,405

Serious

22,633

48% of reports

Hospitalization

7,265

Death reported

909

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective3,872
  • headache2,922
  • fatigue2,894
  • nausea2,892
  • off label use2,418
  • pain2,093
  • diarrhoea1,961
  • dizziness1,736
  • breast cancer female1,709
  • arthralgia1,646
  • pruritus1,568
  • rash1,545
  • product adhesion issue1,536
  • dyspnoea1,535
  • insomnia1,360

Reports by year received

View as table
YearReports
2004524
2005571
2006402
20071,461
2008431
2009601
2010972
2011851
20121,160
2013889
20141,117
20151,923
20162,394
20172,181
20182,581
20192,912
20202,914
20212,861
20223,093
20233,561
20243,713
20255,259
20265,033

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,006,754 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
breast cancer femaleSignal1,70930.328.845,287
product adhesion issueSignal1,53619.918.926,392
insomniaSignal1,3602.32.2975
headacheSignal2,9222.12.01,663
pruritus1,5681.81.7580
arthralgia1,6461.81.7548
fatigue2,8941.71.6769
nausea2,8921.61.6716
rash1,5451.61.5329
dizziness1,7361.51.5341
pain2,0931.51.5374
diarrhoea1,9611.31.3182
drug ineffective3,8721.31.3292
off label use2,4181.21.2104
dyspnoea1,5351.21.154

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.